港股異動 | 大健康國際暴漲1.3倍 獲官方委託為防疫醫療物資指定的採購單位
格隆匯2月11日丨大健康國際(2211.HK)現報0.132港元,暴漲135.71%,暫成交2327萬港元,最新總市值5.1億港元。大健康國際昨晚公佈,為對抗疫症,集團旗下如吉林省、瀋陽地區、黑龍江地區部分附屬公司受當地政府防疫指揮部門委託為防疫醫療物資指定的採購單位。相關附屬公司將進一步發揮集團整體優勢,發揮遍佈東北地區八百餘家連鎖藥房及國內的五大物流配送中心優勢,整合上游商業資源,調動境內外分支機構積極性,盡全力對抗疫症。值得一提的是,因新冠肺炎疫情,今年以來醫藥仙股屢遭資金爆炒,大健康國際2020年迄今已累漲約2倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.